Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IARC 50th Anniversary Conference /
MetAL trial for prostate cancer

7th - 10th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.07.16
Views: 2145

Dr Mieke Van Hemelrijck - Kings College London, London, UK

Dr van Hemelrijck speaks with ecancertv at IARC 2016 about the conflicting results of metformin to treat prostate cancer.

Metformin, a widely available diabetes treatment, is variably associated with slowing or aggravating cancer, which may be due to the apparent protection from cancer associated with diabetes.

In a new trial, Dr van Hemelrijck aims to understand the mechanisms linking metformin, cancer and longevity with pre-surgical and post-operative sample analysis.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation